Istituto Auxologico Italiano IRCCS
- Address
- Piazzale Brescia 20, 20149 Milan, Italy
Istituto Auxologico Italiano IRCCS - Advanced Clinical Research Center
Istituto Auxologico Italiano IRCCS is a distinguished research institution conducting cutting-edge clinical trials across a diverse spectrum of medical specialties. The center demonstrates particular expertise in neurodegenerative disorders, cardiovascular diseases, and endocrine conditions, with a strong focus on rare and complex diseases requiring specialized care and innovative therapeutic approaches.
- Neurological and Neurodegenerative Diseases: Advanced research in Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease-related psychosis and agitation, Frontotemporal Dementia, and Parkinson's disease with motor fluctuations
- Cardiovascular Disorders: Comprehensive studies in hypertrophic cardiomyopathy (both obstructive and non-obstructive), resistant and uncontrolled hypertension, and cardiovascular disease prevention with novel lipoprotein therapeutics
- Endocrine and Autoimmune Conditions: Specialized trials for thyroid eye disease, Grave's disease, Cushing syndrome, and classic congenital adrenal hyperplasia
- Neurological Pain Management: Headache disorder research including episodic and chronic migraine prevention using innovative therapeutic approaches
The institute's research portfolio also encompasses rare autoimmune conditions such as eosinophilic granulomatosis with polyangiitis (EGPA), psychiatric conditions including anorexia nervosa, and heart failure optimization studies with particular attention to sex-based differences in treatment outcomes. With participation in numerous Phase 2 and Phase 3 international trials, Istituto Auxologico Italiano IRCCS serves as a key contributor to advancing medical knowledge and providing patients access to breakthrough therapies across multiple therapeutic domains.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Argenx1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Istituto Auxologico Italiano IRCCS
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome | Janssen Cilag International | Phase III | Not Recruiting | Nov 2023 | Jan 2026 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-11-21 | 2023-11-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.